

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4244227

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
FENG GONG	01/19/2017
XINLU LI	01/19/2017
RUI ZHAO	01/19/2017
XIQUN ZHANG	01/22/2017
XINHE XU	01/22/2017
XIJIE LIU	01/22/2017
DENGMING XIAO	01/22/2017
YONGXIN HAN	01/22/2017

RECEIVING PARTY DATA

Name:	CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
Street Address:	NO. 369 YUZHOU SOUTH RD., HAIZHOU DISTRICT
City:	LIANYUNGANG CITY, JIANGSU
State/Country:	CHINA
Postal Code:	222062
Name:	LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.
Street Address:	NO. 16 JINQIAO ROAD
Internal Address:	DAPU INDUSTRY PARK, LIANYUNGANG ECONOMY AND TECHNOLOGY DEVELOPMENT ZONE
City:	LIANYUNGANG CITY, JIANGSU PROVINCE
State/Country:	CHINA
Postal Code:	222069
Name:	CENTAURUS BIOPHARMA CO., LTD.
Street Address:	NO. 16 BUILDING, NO. 3 MINZHUANG ROAD
City:	HAIDIAN DISTRICT, BEIJING CITY P.R.
State/Country:	CHINA
Postal Code:	100195

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	15329046

CORRESPONDENCE DATA**Fax Number:** (202)737-6776

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (202)737-6770**Email:** assignments@leydig.com**Correspondent Name:** LEYDIG, VOIT & MAYER, LTD.**Address Line 1:** 700 THIRTEENTH STREET NW**Address Line 2:** SUITE 300**Address Line 4:** WASHINGTON, D.C. 20005

ATTORNEY DOCKET NUMBER:	727631
NAME OF SUBMITTER:	STEPHANIE M. LAWLEY
SIGNATURE:	/Stephanie M. Lawley/
DATE SIGNED:	01/26/2017

Total Attachments: 5

source=727631 Executed Assignment#page1.tif

source=727631 Executed Assignment#page2.tif

source=727631 Executed Assignment#page3.tif

source=727631 Executed Assignment#page4.tif

source=727631 Executed Assignment#page5.tif

ASSIGNMENT

WHEREAS, I/WE

- (1) Feng GONG of No. 369 Yuzhou South Rd., Haizhou District, Lianyungang City, Jiangsu 222062, China,
- (2) Xinlu LI of No. 369 Yuzhou South Rd., Haizhou District, Lianyungang City, Jiangsu 222062, China,
- (3) Rui ZHAO of No. 369 Yuzhou South Rd., Haizhou District, Lianyungang City, Jiangsu 222062, China,
- (4) Xiquan ZHANG of No. 369 Yuzhou South Rd., Haizhou District, Lianyungang City, Jiangsu 222062, China,
- (5) Xinhe XU of No. 16 Building, No. 3 Minzhuang Road Haidian District, Beijing City P.R.China, 100195.,
- (6) Xijie LIU of No. 16 Building, No. 3 Minzhuang Road Haidian District, Beijing City P.R.China, 100195.,
- (7) Dengming XIAO of No. 16 Building, No. 3 Minzhuang Road Haidian District, Beijing City P.R.China, 100195.,
- (8) Yongxin HAN of No. 16 Building, No. 3 Minzhuang Road Haidian District, Beijing City P.R.China, 100195.,

hereinafter referred to as Assignor, have invented a certain invention entitled:

PYRIDINE-SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITORS

for which International Patent Application No. PCT/CN2015/085727 has been filed on July 31, 2015, and

WHEREAS,

- (1) CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD, of No. 369 Yuzhou South Rd., Haizhou District, Lianyungang City, Jiangsu 222062, China,
- (2) LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD., of No. 16 Jinqiao Road, Dapu Industry Park, Lianyungang Economy and Technology Development Zone, Lianyungang City, Jiangsu Province 222069, China, and
- (3) CENTAURUS BIOPHARMA CO., LTD., of No. 16 Building, No. 3 Minzhuang Road Haidian District, Beijing City P.R.China, 100195.

hereinafter jointly referred to as Assignee, are desirous of acquiring the entire U.S. right, title, and interest of Assignor in, to, and under the invention and the referenced International Patent Application, including the entire right, title, and interest of Assignor in, to, and under the U.S. national phase thereof, filed on January 25, 2017 as U.S. Patent Application No. 15/329,046 ,

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Assignor assigns and transfers to Assignee the entire U.S. right, title, and interest of Assignor in, to, and under the invention, the referenced International Patent Application and U.S. national phase thereof, and other such U.S. patent applications (e.g., continuations, continuations-in-part, divisionals, reissues, and reexaminations) that may be filed in the U.S. with a claim of priority to the referenced International Patent Application and/or the U.S. national phase application thereof, as well as U.S. patents that may issue thereon and that may be modified as the result of applicable procedures (e.g., supplemental examinations, ex parte reexaminations, inter partes reexaminations, inter partes reviews, and post-grant reviews),

Assignor conveys to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and to claim priority in the U.S. to the aforementioned patent applications and any priority documents referenced therein under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue the U.S. patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. on the invention, and in enforcing any rights accruing as a result of such U.S. applications or patents, by, for example, executing statements and other affidavits,

Assignor and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor authorizes Assignee to insert in this assignment the number and filing date of the U.S. patent application if the number and filing date of the U.S. patent application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor and Assignee agree that U.S. law governs this assignment, and

Assignee acknowledges and accepts this assignment.

IN WITNESS WHEREOF, Assignor has hereunder set his/her hand on the date shown below.

Date January 19, 2017

Feng GONG
Assignor: Feng GONG

Date January 19, 2017

Tiang Huang
Witness:

Date January 19, 2017

Tie YANG
Witness:

=====
Date January 19, 2017

Xinlu LI
Assignor: Xinlu LI

Date January 19, 2017

Tiang Huang
Witness:

Date January 19, 2017

Tie YANG
Witness:

=====
Date January 19, 2017

Rui ZHAO
Assignor: Rui ZHAO

Date January 19, 2017

Tiang Huang
Witness:

Date January 19, 2017

Tie YANG
Witness:
=====

In re Appln. of GONG et al.
Attorney Docket No. 727631

Date _____

Xiquan Zhang
Assignor: Xiquan ZHANG

Date January 22, 2017

Sainan Wang
Witness:

Date _____

Yu Jin
Witness:

Date _____

Xinhe Xu
Assignor: Xinhe XU

Date _____

[Signature]
Witness:

Date _____

Yan Zhiu
Witness:

Date _____

Xijie Liu
Assignor: Xijie LIU

Date _____

[Signature]
Witness:

Date _____


Yan Zhiu
Witness:

In re Appln. of GONG et al.
Attorney Docket No. 727631


Date _____


Assignor: Dengming XIAO


Date _____


Witness: _____


Date _____


Witness: _____


Date _____


Assignor: Yongxin HAN

Date _____


Witness: _____

Date _____


Witness: _____